Targeted Therapy

The Phase III STELLAR trial found that combining Eflornithine with Lomustine significantly improves outcomes for patients with recurrent IDH-mutant Grade 3 Astrocytoma, an aggressive type of brain tumor. While the combination did not benefit the entire study population, patients in this specific molecular subgroup saw median overall survival increase from 23.5 months with lomustine alone […]

Researchers have developed a new targeted nanomedicine that combines chemotherapy and immunotherapy to treat Colorectal Cancer. The therapy uses irinotecan loaded into nanoparticles coated with molecules that specifically bind to CD44v6, a protein commonly found on metastatic colorectal cancer cells. This approach allows the chemotherapy to reach tumors more precisely while boosting the immune system

Long-term results from the CheckMate 9ER trial show that deeper tumor shrinkage is strongly linked to longer survival in patients with advanced Renal Cell Carcinoma treated with a combination of Cabozantinib (Cabometyx) and Nivolumab (Opdivo). The findings, presented in early 2026, come from a long-term follow-up of about 67 months. Researchers found that patients who

A new study reveals that the protein L1CAM (CD171) plays a key role in driving the aggressive spread of Glioblastoma (GBM) cells into healthy brain tissue. Glioblastoma is notoriously difficult to treat because its cells migrate away from the main tumor, leading to relapse. Researchers used patient-derived neurosphere cells grown in serum-free conditions to better

A post hoc analysis of the Phase 2 eNRGy trial, presented at the 2026 TTLC Meeting, suggests that continuing Zenocutuzumab-zbco (Bizengri) after initial disease progression can provide meaningful benefits for patients with NRG1 fusion-positive non-small cell lung cancer (NSCLC). Standard practice often stops a therapy when imaging shows progression, but the study found that many

Researchers have developed a new genome-editing tool designed to target pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers. The team engineered an improved cytosine base editor using a human protein called APOBEC3F. By combining artificial intelligence–based protein modeling with structure-guided engineering, they created optimized versions that improve editing efficiency and accuracy while reducing unwanted

Antibody–drug conjugates (ADCs) are emerging as a promising targeted treatment for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers with a five-year survival rate of about 10%. PDAC is difficult to treat because tumors are surrounded by dense fibrotic tissue that blocks drug delivery. The disease is also highly diverse at the molecular level

A study shows that combining anti-estrogen therapy with metabolic-targeted treatments—like metformin for diabetes or insulin resistance, statins for dyslipidemia, and calcium channel blockers for hypertension—can enhance fertility-preserving outcomes in endometrial cancer (EC) and endometrial atypical hyperplasia (EAH). Among 285 patients treated, 77% achieved complete response within six months, and pregnancy and live birth rates reached 38%

PROTAC technology represents a major shift in modern drug design, moving beyond protein inhibition toward directly eliminating disease-causing proteins. Unlike traditional drugs that must block a specific active site, PROTACs work by guiding unwanted proteins to the cell’s natural disposal system. Once the protein is tagged and destroyed, the PROTAC molecule is released and can

Elevar Therapeutics has asked the FDA to approve lirafugratinib (RLY-4008) as a second-line treatment for cholangiocarcinoma, a rare bile duct cancer, in patients with FGFR2 gene changes. The request is based on the ReFocus trial, which included 116 patients who had already had chemotherapy but not another FGFR-targeted drug. The drug showed a 46.5% overall